New CAR-T study aims to boost cancer treatment success
NCT ID NCT05366569
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well CAR-T cell therapy works for people with certain blood cancers like lymphoma and leukemia. Researchers will track how the modified immune cells grow and last in the body after infusion. The goal is to see if this treatment is effective in real-world settings, not just in controlled trials.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CAR-T cell therapy
- What this could lead to
- If successful, this could help improve how CAR-T cell therapy is used for blood cancers, potentially leading to better treatment outcomes.
- What could go wrong
- This is an early-stage study with only 45 participants, so results may not apply to everyone. CAR-T therapy can cause serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
ASST Spedali Civili di Brescia
RECRUITINGBrescia, 25123, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug combo keep aggressive lymphoma at bay?
- Can donor immune cells be engineered to fight blood cancer?
- Can a 'Universal' cancer target outsmart resistant blood cancers?
- Fighting sedentary time in young cancer patients: a digital intervention put to the test
- Can a Chemo-Antibody combo beat a tough leukemia?
- Can a single shot build a cancer army inside the body?